Standout Papers

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma 2019 2026 2021 2023 444
  1. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2019)
    Laurie H. Sehn, Alex F. Herrera et al. Journal of Clinical Oncology
  2. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study (2022)
    Jeremy S. Abramson, Scott R. Solomon et al. Blood

Immediate Impact

1 by Nobel laureates 57 standout
Sub-graph 1 of 21

Citing Papers

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
2 intermediate papers

Works of Manali Kamdar being referenced

Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.
2022
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2019 Standout

Author Peers

Author Last Decade Papers Cites
Manali Kamdar 1005 785 270 87 1.3k
Annette E. Hay 996 809 216 79 1.5k
Xiaonan Hong 1018 905 298 71 1.6k
Amitkumar Mehta 800 491 200 113 1.2k
Jamie Hirata 1011 1039 398 64 1.4k
Javier Muñoz 1147 847 518 129 1.7k
Connie Lee Batlevi 728 423 191 76 1.1k
Peter A. Riedell 995 505 214 109 1.4k
Tycel Phillips 858 905 521 147 1.5k
Weiyun Z. Ai 952 546 148 64 1.5k
Clémentine Sarkozy 736 961 342 70 1.3k

All Works

Loading papers...

Rankless by CCL
2026